No Increased Risk of Skeletal Events in Patients With Bone Metastases Taking Zoledronic Acid
A new study published in JAMA reported that patients with bone metastases due to breast cancer, prostate cancer, or multiple myeloma who used zoledronic acid every 12 weeks compared with every 4 weeks did not have in an increased risk of skeletal events over 2 years.
In this study, Andrew L. Himelstein, MD, of the Helen F. Graham Cancer Center & Research Institute, Newark, Delaware, and colleagues reported that zoledronic acid, a third-generation aminobisphosphonate, reduces the incidence of skeletal-related events and pain in patients with bone metastases. Among patients with bone metastases due to breast cancer, prostate cancer, or multiple myeloma, the use of zoledronic acid every 12 weeks compared with the standard dosing interval of every 4 weeks did not result in an increased risk of skeletal events over 2 years. This longer interval may be an acceptable treatment option.
In the randomized, open-label, noninferiority clinical trial of 1,822 patients with metastatic breast cancer, metastatic prostate cancer, or multiple myeloma, 795 completed the study, among whom 29.5% of patients receiving zoledronic acid every 4 weeks and 28.6% of patients receiving zoledronic acid every 12 weeks experienced at least 1 skeletal-related event within 2 years of randomization, meeting criteria for noninferiority.
The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.
